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We	examined	the	effects	of	post-ischemic	blockade	of	angiotensin	AT1	receptors	by	candesartan	
on	cerebral	infarction	and	formation	of	edema.	Male	Sprague–Dawley	rats	were	divided	into	
three	groups,	sham,	control	ischemic,	and	candesartan-treated	(0.3	mg/kg)	ischemic.	Transient	
focal	 cerebral	 ischemia	was	 induced	 by	 90-min-long	 occlusion	 of	 the	 left	middle	 cerebral	
artery	followed	by	24-h-long	reperfusion.	Neurological	deficit	score	was	evaluated	at	the	end	
of	the	reperfusion	period.	Thereafter,	the	animals	were	randomly	selected	and	used	for	three	
projects:	(i)	Measurement	of	the	infarct	volumes,	(ii)	investigation	of	ischemic	brain	edema	
formation	using	a	wet/dry	method,	and	(iii)	assessment	of	the	malondialdehyde	(MDA)	and	
reduced	 glutathione	 (GSH)	 concentrations	 using	 a	 HPLC	 technique.	 Induction	 of	 cerebral	
ischemia	 in	 the	control	group	produced	considerable	 infarctions	 in	 the	cortex	and	 striatum	
in	conjunction	with	severely	impaired	motor	functions.	Candesartan	treatment	significantly	
reduced	the	infarct	volumes	and	improved	the	above	functions.	The	water	content	in	the	left	
(lesioned)	hemisphere	was	considerably	elevated	in	the	control	ischemic	group.	Candesartan	
treatment	 significantly	 lowered	 the	 water	 content	 in	 the	 ischemic	 lesioned	 hemisphere,	
retained	 tissue	GSH	 level,	 and	 led	 to	 a	 lower	MDA	production.	AT1	 receptor	 blockade	by	
candesartan	 treatment	 can	 noticeably	 decrease	 ischemic	 brain	 injury	 and	 attenuate	 edema	
formation,	likely	via	increasing	the	antioxidant	activity.	
Keywords: focal cerebral ischemia, brain edema, candesartan, malondialdehyde, 
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INTRODUCTION
With	an	around	30%	mortality	rate,	stroke	remains	the	
third	leading	cause	of	death	in	industrialized	countries.	
Ischemic	brain	injury	results	from	a	complex	sequence	
of pathophysiological events developing over time and 
space	[1].	The	extent	of	the	tissue	damage	depends	on	
both	intensity	and	duration	of	focal	cerebral	ischemia	
[2].	 Ischemic	 brain	 edema	 is	 a	 life-threatening	
complication	 of	 cerebral	 infarction	 that	 significantly	
aggravates	 the	 primary	 ischemic	 injury	 of	 the	 brain	
[3]	via	 increased	 intracranial	pressure	and	herniation	
[1].	 Therefore,	 prevention	 from	 the	 development	 of	
brain	edema	may	decrease	cerebral	injury	and	reduce	
stroke-related	mortality.
Experimental 	 and	 cl inical 	 s tudies 	 al lowed	
researchers	 to	 suggest	 that	 inhibition	 of	 the	 renin-
angiotensin	system	(RAS)	by	 inactivation	of	ACE	or	
angiotensin	1	 (AT1)	 receptors	might	be	effective	not	
only	 in	 reducing	 the	 occurrence	 of	 stroke,	 but	 also	
may	attenuate	neuronal	injury	[4].	Furthermore,	long-
term	pretreatment	with	ACE	inhibitors	or	AT1	receptor	
blockers	 was	 reported	 to	 prevent	 the	 occurrence	 of	
cerebral	 ischemia	 in	 stroke-prone	 spontaneously	
hypertensive	 rats	 [5-7].	Other	 reports	 also	 indicated	
that	 inhibition	of	ACE	[8]	or	AT1	receptors	 [9]	prior	
to the induction of ischemia improve neurological 
recovery	 from	 cerebral	 ischemia.	 There	 are	 a	 few	
studies	 of	 the	 effects	 of	 post-ischemic	AT1	 receptor	
blockade	on brain	 ischemic/reperfusion	(I/R)	 injuries	
and	their	mechanisms.
Oxygen	free	radicals	may	play	a	noticeable	role	 in	
brain	 I/R	 injuries.	 The	 amount	 of	 oxygen	 provided	
during	 reperfusion	 exceeds	 the	 capabilities	 of	
mitochondrial	 utilization.	Therefore,	 a	 shift	 towards	
high	 production	 of	 free	 radical-related	 compounds,	
such	 as	 NO,	 superoxide,	 hydrogen	 peroxide,	 and	
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hydroxyl,	is	formed	[10].	These	agents	are	constantly	
scavenged	 by	 superoxide	 dismutase,	 glutathione	
peroxidase,	and	catalase.	Other	antioxidants,	including	
reduced	glutathione	(GSH),	ascorbic	acid,	and	vitamin	
E,	 are	 also	 likely	 to	 be	 involved	 in	 detoxification	
of	 the	 free	 radicals.	When	 endogenous	 antioxidant	
mechanisms are suppressed or the production of free 
radicals	 outweighs	 these	 mechanisms,	 a	 chain	 of	
reactions	 (denaturation	 of	 proteins,	 inactivation	 of	
enzymes,	and	breaking	down	of	carbohydrates)	starts.	
This leads to intense lipid peroxidation in the inner 
and	outer	mitochondrial	and	cell	membranes	[11].
As	 the	 RAS	 and	 inflammatory	 responses	 play	
important	roles	in	I/R	injuries,	our	study	was	designed	
to evaluate the neuroprotective effects of post-
ischemic	treatment	with	candesartan,	an	AT1	receptor	
antagonist,	and	the	mechanisms	of	these	effects.
METHODS
Fifty-four	 male	 Sprague-Dawley	 rats	 (280-320	 g)	 
were	obtained	 from	the	Central	animal	house	 facility	
of	 the	 Ardabil	 University	 of	 Medical	 Sciences	
(Ardabil,	Iran).	Anesthesia	was	made	by	i.p.	injections	
of	chloral	hydrate	(400	mg/kg).	Body	temperature	was	
maintained	 at	 37	 ±	 0.5°C	 with	 a	 heating	 feedback	
control	system. 
Laser Doppler Flowmetery.	 Regional	 cerebral	
blood	 flow	 (rCBF)	 was	 monitored	 in	 the	 cerebral	
cortex	 of	 the	 left	 hemisphere	 within	 the	 territory	
supplied	by	 the	middle	cerebral	 artery	 (MCA)	using	
a	 laser	 Doppler	 flowmeter	 pencil	 probe	 (MNP100,	
AD	 Instrument,	Australia).	 Following	 dissection	 of	
the left m. temporalis	between	 the	eye	and	 the	ear,	a	
burr	hole	was	drilled	5	mm	lateral	and	1	mm	posterior	
to	 the	 bregma	 [12].	 To	 prevent	 displacement	 of	 the	
probe,	 rCBF	was	continuously	measured	from	before	
MCA	 occlusion,	 during	 such	 occlusion,	 and	 during	
the	 first	 10	min	 of	 reperfusion	 time.	 Baseline	 CBF	
values	 measured	 before	 occlusion	 were	 defined	 as	
100%.	Occlusion	of	the	MCA	was	documented	by	the	
decrease	in	laser	Doppler	signals	to	lower	than	20%	of	
the	baseline.
Experimental  Protocol .  Effects  of  pos t -
ischemic	 candesartan	 treatment	 on	 brain	 injury	 and	
neurological	score	were	investigated	in	the	following	
randomly	 divided	 three	 groups	 of	 animals:	 group	 
1 (sham	group,	n	=	6),	 rats	underwent	surgery	at	 the	
neck	 region	 with	 no	 occlusion	 of	 the	 MCA,	 group	
2	 (control	 ischemic	 group,	 n =	 6),	 rats	 experienced	
brain	 ischemia	 by	 90-min-long	 MCA	 occlusion	
followed	 by	 24-h-long	 reperfusion	 and	 received	 the	
vehicle	 (normal	 saline,	 1	 ml/kg)	 at	 the	 beginning	
of	 the	 reperfusion	 period,	 and	 group	 3 (candesartan 
post-treated	 ischemic	group,	n	=	6),	 rats	experienced	
ischemia	 and	 reperfusion	 similarly	 to	 group	 2,	 but	
received	i.p.	injections	of	candesartan	(0.3	mg/kg,	LKT	
laboratories,	USA)	at	the	beginning	of	reperfusion.	
Assessment of the effects of post-ischemic 
candesartan	 treatment	 on	 the	 formation	 of	 brain	
edema and measurement of the level of tissue 
malondialdehyde	 (MDA)	 as	 a	 marker	 of	 lipid	
peroxidation and that of tissue reduced glutathione 
(GSH)	 as	 a	marker	 of	 the	 antioxidant	 capacity	were	
done	in	another	six	parallel	groups	(n	=	6	in	each)	of	
animals	under	the	same	conditions	as	in	groups	1-3.	
Induction of Transient Focal Cerebral Ischemia. 
Ninety-minute-long occlusion of the MCA and 
24-h-long	reperfusion	of	 the	 left	cerebral	hemisphere	
were	 carried	 out	 using	 an	 intraluminal	 filament	
method	described	by	Longa	et	al.	[13]	and	modified	by	
Panahpour	et	al.	[14].	Briefly,	the	left	common	carotid	
artery	was	exposed	 through	a	midline	neck	 incision.	
Through	 this	artery,	a	 surgical	nylon	silicone-coated	
thread	 (4-0	 Ethilon)	 was	 placed	 into	 the	 internal	
carotid artery and gently advanced up until seeing a 
sharp	decline	in	the	blood	flow	trace	is	seen.	Occlusion	
was	terminated	by	gently	pulling	out	the	thread.	After	
re-establishment	 of	 the	 blood	 flow,	 all	 the	 incisions	
were	 sutured;	 the	 animals	 were	 allowed	 to	 recover	
from	 anesthesia	 and	 returned	 to	 a	 warm	 cage	 for	
recuperation	during	the	24-h-long	reperfusion	period.	
Behavioral	 tests	 were	 performed	 by	 a	 blinded	
observer	 24	 h	 after	 surgery	 in	 the	 sham	 group	 or	 
24	 h	 after	 MCA	 occlusion	 in	 the	 ischemic	 groups.	
As	 was	 described	 previously,	 the	 five-point	 scale	
grading	 neurological	 deficit	 score	 (NDS)	 test	 was	
carried	out	to	evaluate	the	neurological	outcome	[14].	
Rats	with	normal	motor	function	were	graded	1.	Rats	
with	 contralateral	 flexion	 of	 the	 body	 or	 forelimb	
upon	 lifting	 by	 the	 tail	were	 graded	2.	Grade	 3	was	
assigned to dysfunctional rats circling to the side 
contralateral	with	 respect	 to	occlusion.	Grade	4	was	
assigned	 to	 rats	with	 loss	 of	 the	 righting	 reflex	 and	
decreased	 resistance	 to	 lateral	 push;	 finally,	 grade	
5	 characterized	 rats	 having	 no	 spontaneous	 motor	
activity.	After	 the	NDS	 test,	 animals	were	sacrificed	
under	 deep	 anesthesia;	 the	 brain	 was	 removed,	
cleaned,	 and	 solidified	 by	 immersion	 in	 cold	 saline	
(4°C).	Frontal	2-mm-thick	slices	were	prepared	using	
a	brain	matrix	and	stained	with	 triphenyltetrazolium	
chloride	 (TTC),	 as	 was	 described	 previously	 
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[14,	15].	After	staining,	the	slice	images	were	digitized	
using	 a	 Cannon	 camera,	 and	 the	 cerebral	 infarction	
areas	were	measured	with	computer-based	NIH	image	
analyzer	software	[14,	15].	
Ischemic	 brain	 edema	 was	 assessed	 using	 a	 dry/
wet	 method	 according	 to	 the	 technique	 presented	
by	Gerriets	 et	 al.	 [16].	 The	 normalized	 brain	water	
content	 (WC)	for	each	hemisphere	was	calculated	by	
measuring	the	wet	weight	(WW)	and	dry	weight	(DW)	
of	 the	 ipsilateral	 (lesioned)	 and	 contralateral	 (non-
lesioned)	hemispheres	by	the	following	equation:
WC	(%)	=	[(WW	–	DW)/WW]	∙	100%.
Preparation of Tissue Samples. Twenty-four	
hours	after	 the	beginning	of	 reperfusion,	 the	animals	
were	 decapitated.	 The	 brain	 was	 removed,	 and	 the	
ischemic	 area	 (core	 and	 penumbra	 regions)	 of	 the	
ipsilateral	 hemisphere	 was	 dissected	 according	 to	
the	 well-known	 protocols	 for	 rodent	 models	 with	
unilateral	 MCA	 occlusion	 [17,	 18].	 Briefly,	 the	
brain	 was	 sectioned	 into	 three	 slices	 beginning	
3	 mm	 from	 the	 anterior	 tip	 of	 the	 frontal	 lobe.	
In	 section	 2	 (4	 mm	 thick),	 the	 ischemic	 area	 was	
dissected	 with	 a	 longitudinal	 cut	 approximately	 
2	mm	from	 the	midline.	The	 tissue	was	weighed	and	
homogenized	 in	 PBS	with	 a	weight-to-volume	 ratio	
1:5.	The	homogenate	was	centrifuged	(10,000g,	4°C)	
for	 30	min.	 The	 supernatants	 for	 each	 sample	were	
separated	in	Eppendorf	 tubes	and	kept	at	–80°C	until	
analysis.
Estimation of  Lipid Peroxidation.  Lipid 
peroxidation	 was	 evaluated	 by	 measuring	 the	
MDA	 concentration	 in	 brain	 samples.	 The	 MDA	
levels	 were	 measured	 using	 a	 high-performance	
liquid	 chromatography	 (HPLC)	 method	 [19]	 with	
some	 modifications.	 Briefly,	 a	 100	 ml	 aliquot	 of	
the	 supernatant	 was	 placed	 in	 a	 1.5-ml	 Eppendorf	
tube,	 and	 50	ml	 of	 6	M	NaOH	was	 added.	Alkaline	
hydrolysis	 of	 protein-bound	 MDA	 was	 achieved	
by	 incubating	 this	mixture	 in	 a	 60°C	water	 bath	 for	 
30	 min.	 Then,	 protein	 was	 precipitated	 with	 50	 ml	
of	 35%	 (v/v)	 perchloric	 acid,	 and	 the	 mixture	 was	
centrifuged	 at	 2,800g	 for	 10	min.	A	 100	ml	 volume	
of	 the	 supernatant	 was	 transferred	 to	 an	 Eppendorf	
tube	and	mixed	with	10	ml	2,4-nitrophenylhydrazine	
(DNPH)	 prepared	 as	 a	 5	 mM	 solution	 in	 2	 M	
hydrochloric	acid.	Finally,	 this	 reaction	mixture	was	
incubated	 for	30	min	at	 room	 temperature	 (protected	
from	 light).	A	50	ml	 aliquot	 of	 the	 reaction	mixture	
was	 injected	 into	 the	HPLC	system	equipped	with	 a	
C18	column	(4.6´250	mm,	5	µm	particle	size).	Results	
were	expressed	in	nanomoles	per	one	milligram	of	wet	
tissue	weight.
Estimation of GSH. The concentration of reduced 
GSH	 as	 an	 important	 biomarker	 of	 the	 antioxidant	
defense	capacity	was	also	measured	using	 the	HPLC	
method	 [20]	with	some	modifications.	Briefly,	a	100	
ml	volume	of	the	sample	supernatant	was	placed	in	an	
Eppendorf	vial	 and	diluted	with	 an	 equal	volume	of	
trichloroacetic	acid	 (5%	final	concentration	w/v)	and	
centrifuged	at	10,000g	for	15	min.	A	100	ml	volume	
of	the	supernatant	was	transferred	to	a	new	Eppendorf	
vial.	After	alkalization,	 the	 sample	was	 reacted	with	
an	equal	volume	of	2,4-dinintrofluorobenzene	solution	
(1.5%	in	ethanol	v/v)	 for	1	h	at	 room	temperature	 in	
the	 dark.	After	 acidification	 with	 10	 ml	 HCl	 (37%	
initial	 concentration	 v/v),	 50	ml	 of	 the	 sample	was	
loaded	 onto	 the	 HPLC.	 Results	 were	 expressed	 in	
millimoles	per	one	milligram	of	wet	tissue	weight.
Statistical  Analysis.  Numerical  values are 
expressed	as	means	±	s.e.m. The independent t-test and 
one-way	ANOVA	with	 the	post-hoc Holm-Sidak	 test	
were	used	for	comparisons. The statistical significance 
was	accepted	at	P	<	0.05.
RESULTS
Cerebral Blood Flow Recording.	 The	 rCBF	 value	
was	 reduced	 to	 less	 than	20%	baseline	 in	 the	control	
and candesartan-treated ischemic groups after MCA 
occlusion.	There	was	no	significant	difference	between	
rCBF	 values	 in	 the	 groups	 during	 occlusion	 and	 the	
first	10	min	of	reperfusion	(Fig.	1).
Evaluation of NDS. The	 mean	 NDS	 of	 control	
ischemic	rats	(4.3	±	0.6)	was	dramatically	higher	than	
that	of	sham-operated	rats	(1.00;	P	<	0.01).	The	NDS	
of	ischemic	rats	receiving	0.3	mg/kg	candesartan	post-
ischemically	(1.67	±	0.2)	was	significantly	lower	(less	
than	40%)	than	that	of	control	ischemic	rats	(P	<	0.05).
Assessment of the Cerebral Infarct Volumes. 
Sham-operated	 rats	 had	 no	 infarctions.	 The	 total	
infarct	 volume	 in	 ischemic	 rats	 receiving	0.3	mg/kg	 
candesartan	 was	 significantly	 smaller	 than	 that	 in	
control	 ischemic	 rats	 (P	 <	 0.01).	 When	 compared	
to	 control	 ischemic	 animals,	 candesartan-treated	
ischemic rats had significantly smaller cortical and 
striatal	infarct	volumes	(P	<	0.05;	Fig.	2).
Assessment of Ischemic Brain Edema. There 
was	 no	 statistically	 significant	 difference	 between	
the	 right-side	water	content	 in	 the	brains	of	 animals	
of	 the	 experimental	 groups.	 Moreover,	 there	 was	
no	 significant	 difference	 between	 the	 left-side	 and	
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F i g. 1.	Normalized	values	of	regional	cerebral	blood	flow	in	control	 ischemic	rats	(ﬁlled	columns,	n	=	5)	and	ischemic	rats	 that	
received	0.3	mg/kg	candesartan	(dashed	columns,	n =	5)	during	occlusion	of	the	middle	cerebral	artery	(MCAO)	and	at	the	beginning	
of	reperfusion	(REP).	
Р и с. 1.	Нормовані	величини	місцевого	кровотоку	в	контрольних	щурів	з	ішемією	(чорні	стовпчики,	n =	5)	та	ішемізованих	тварин,	
котрі	отримували	0.3	мг/кг	кандесартану	(заштриховані	стовпчики,	n =	5),	протягом	оклюзії	середньої	церебральної	артерії	та	на	
початку	реперфузії.
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F i g. 2.	 Total,	 cortical,	 and	 subcortical	 infarct	 volumes,	 mm3,	 
in control ischemic rats and ischemic rats that received candesartan 
at	 the	 beginning	 of	 reperfusion	 (ﬁlled	 and	 dashed	 columns,	
respectively).	Asterisks	 indicate	 signiﬁcant	differences	 (P	<	0.05)	
from	control	rats.
Р и с. 2.	 Сумарні,	 кортикальні	 та	 субкортикальні	 об’єми	 зон	
інфаркту	(мм3)	у	контрольних	щурів	з	ішемією	та	ішемізованих	
тварин,	 котрі	 отримували	 кандесартан,	 на	 початку	 реперфузії	
(чорні	та	заштриховані	стовпчики	відповідно).
F i g. 3.	Normalized	values	of	the	brain	water	content	in	the	left	and	
right	 hemispheres	 (ﬁlled/dashed	 and	 gray	 columns,	 respectively)	
in	sham-operated	animals,	control	ischemic	rats,	and	ischemic	rats	
that	received	candesartan	(0.3	mg/kg).	Asterisk	indicates	signiﬁcant	
difference	 (P	 <	 0.05)	 from	 the	 control	 group;	 cross	 indicates	
signiﬁcant	difference	(P	<	0.05)	from	the	sham	group.
Р и с. 3.	 Нормовані	 величини	 вмісту	 води	 в	 лівій	 та	 правій	
півкулях	 мозку	 (чорні	 та	 заштриховані/сірі	 стовпчики	
відповідно)	 в	 інтактних	 контрольних	 щурів,	 контрольних	
тварин	 з	 ішемією	 та	 ішемізованих	 щурів,	 котрі	 отримували	
кандесартан	(0.3	мг/кг).
right-side	 water	 contents	 in	 the	 brains	 of	 sham-
operated	 rats.	 The	 left	 (ischemic)-side	 brain	 water	
content	of	 control	 ischemic	 rats	 (83.1	±	0.46%)	was	
significantly greater than that in sham-operated rats 
(P	<	0.01).	Post-ischemic	 treatment	with	candesartan	
(0.3	 mg/kg)	 was	 associated	 significantly	 with	 the	
lower	 left-side	 brain	 water	 content	 (80.9	 ±	 0.81%)	
than	 that	 in	 control	 ischemic	 rats	 (81.6	 ±	 0.45%,	 
P	<	0.05;	Fig.	3).	
Assessment of MDA and GSH. Ninety-minute-
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long	ischemia	and	24-h-long	reperfusion	in	the	control	
ischemic	group	resulted	in	significantly	reduced	GSH	
and increased MDA concentrations in the left side 
of	 the	 brain	 tissue,	 as	 compared	 to	 the	 sham	 group	 
(P	 <	 0.01).	 Post-ischemic	 candesartan	 treatment	
provided	a	significantly	increased	GSH	concentration	
and	a	reduced	MDA	concentration,	as	compared	to	the	
corresponding figures in the control ischemic group 
(P	<	0.05,	Figs.	4	and	5).
DISCUSSION
The	 renin-angiotensin	 system	 has	 been	 shown	
to significantly participate in the pathogenesis 
of	 ischemic	 events,	 including	 stroke	 [4,	 21,	 22].	
Most of the actions of Ang II are mediated through 
AT1	 receptors.	 Since	 these	 receptors	 contribute	
to	 stroke-related	 pathophysiologic	 mechanisms,	
such	 as	 hypertension,	 atherothrombosis,	 and	
cardiac	 hypertrophy	 [23],	 it	 is	 possible	 that	 Ang	 II	 
aggravates	 I/R	 injuries	 through	 stimulation	 of	 AT1	
receptors.	Previous	 studies	 showed	 that	 pre-ischemic	
RAS	inhibition	provides	protective	effects	with	respect	
to	ischemic	brain	injuries	[14,	24,	25].	Our	study	was	
carried out to evaluate the effects of post-ischemic 
candesartan	 treatment	 on	 ischemic	 brain	 injuries	
and	 edema	 formation.	 Candesartan	 freely	 crosses	
the	 blood-brain	 barrier	 and	 produces	 an	 effective	
and	 long-lasting	 blockade	 of	 cerebral	AT1	 receptors	 
[4,	26].
The	results	of	our	study	demonstrate	 that	blocking	
of	AT1	receptors	significantly	reduces	the	cortical	and	
striatal infarct volumes and improves neurological 
motor	 deficits.	This	 study	 also	 shows	 that	 transient	
ischemia	 induces	 brain	 edema	 by	 increasing	 the	
water	 content	 in	 the	 ischemic	 hemisphere,	 while	
post-ischemic candesartan treatment significantly 
reduces	 the	 water	 content	 in	 the	 above	 hemisphere	
and	 prevents	 edema	 formation.	 These	 findings	 are	
in	 agreement	 with	 reports	 of	 other	 investigators	
demonstrating	 that	 blocking	 of	 AT1	 receptors	
with	 candesartan	 reduced	 the	 infarct	 size	 evoked	
by	 transient	 cerebral	 ischemia	 in	 hypertensive	 
rats	[27,	28].	
Various	mechanisms	might	 be	 responsible	 for	 the	
beneficial	effects	of	the	AT1	receptor	blockade	in	brain	
ischemia.	 Such	 effects	might	 be	 partly	 attributed	 to	
the	stabilizing	action	on	the	impaired	cerebrovascular	
autoregulation	 within	 the	 penumbra	 [29-31].	 In	
addition,	 anti-apoptotic	 mechanisms	 may	 enhance	
the	 protective	 effects	 of	 blocking	 of	AT1	 receptors	
[32].	 Furthermore,	 the	 beneficial	 effects	 of	 the	AT1	
blockade	might	also	be	attributed	to	a	reduction	in	the	
production	of	ROSs	[33].
Cerebral	 ischemia	 is	 associated	 with	 excessive	
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F i g. 4.	 Concentration	 of	 malondialdehyde	 (nmol/mg	 brain	
wet	 tissue)	 in	 sham-operated	 animals,	 control	 ischemic	 rats,	
and	 ischemic	 rats	 that	 received	 candesartan	 at	 the	 beginning	 of	
reperfusion.	 Asterisk	 indicates	 signiﬁcant	 difference	 (P	 <	 0.05)	
from	 control	 ischemic	 rats;	 cross	 indicates	 signiﬁcant	 difference	 
(P	<	0.01)	from	sham-operated	rats.	
Р и с. 4.	 Концентрація	 малондіальдегіду	 (нмоль/мг	 вологої	
тканини	 мозку)	 в	 інтактних	 контрольних	щурів,	 контрольних	
тварин	 з	 ішемією	 та	 ішемізованих	 щурів,	 котрі	 отримували	
кандесартан	на	початку	реперфузії.
F i g. 5.	 Concentration	 of	 reduced	 glutatione	 (mmol/mg	 brain	
wet	 tissue)	 in	 sham-operated	 animals,	 control	 ischemic	 rats,	 and	
ischemic	rats	that	received	candesartan.	Other	designations	are	the	
same	as	in	Fig.	4.	
Р и с. 5.	 Концентрація	 відновленого	 глутатіону	 (нмоль/мг	 
вологої	 тканини	 мозку)	 в	 інтактних	 контрольних	 щурів,	
контрольних	 тварин	 з	 ішемією	 та	 ішемізованих	 тварин,	 котрі	
отримували	кандесартан.
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production	 of	 ROSs,	 especially	 of	 superoxide	 [34].	
The	 production	 of	 ROSs	 initiates	 chain	 reactions,	
causing damage of cellular macromolecules and 
promoting	the	mitochondrial	apoptosis	pathway,	which	
ultimately	leads	to	cell	death	[35].	Our	study	showed	
that	 candesartan	 inhibits	 ROS	 generation,	 increases	
glutathione	production,	and	reduces	MDA	production.	
These	findings	are	in	agreement	with	other	reports	that	
showed	that	activation	of	AT1	receptors	results	in	the	
intense	 production	 of	 superoxide,	whereas	 blockade	
of	these	receptors	is	associated	with	reductions	in	the	
amounts	of	superoxide	[33]and	peroxynitrite	[36].	
The findings of our study also indicated that 
inhibition	of	RAS	by	blocking	AT1	receptors	reduces	
ischemic	edema	formation.	Recent	evidence	suggests	
that	 Ang	 II	 may	 be	 an	 important	 stimulus	 for	 the	
production	of	 superoxide	 and	peroxynitrite	 in	 blood	
vessels	[36].	Oxygen-derived	free	radicals	are	known	
to	 increase	 the	 permeability	 of	 the	 blood-brain	
barrier	 [37].	 Our	 results	 showed	 that	 candesartan	
treatment suppresses lipid peroxidation and increases 
the	 endogenous	 antioxidant	 defense	 capacity.	 Thus,	
blocking	 of	 AT1	 receptors	 may	 reduce	 ischemic	
edema	via	protective	effects	on	the	blood-brain	barrier	
integrity	by	reduction	of	the	ROS	production.	
Therefore,	 inhibition	of	RAS	by	 the	AT1	 receptor	
blocker	 candesartan	 noticeably	 reduces	 the	 cerebral	
infarction volume and edema formation in rats 
exposed	 to	 transient	MCA	occlusion.	The	 respective	
mechanisms	 may	 be	 attributed	 to	 inhibition	 of	
lipid peroxidation and increase in the endogenous 
antioxidant	capacity.
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Р	е	з	ю	м	е
Досліджували	 ефекти	 постішемічного	 блокування	 ангіо-
тензивних	рецепторів	AT1	кандесартаном	щодо	зони	цереб- 
рального	інфаркту	та	формування	набряку.	Самці	щурів	лі-
нії	 Спрейг–Доулі	 були	 розділені	 на	 три	 групи	 (інтактних	
контрольних,	контрольних	з	 ішемією	та	 ішемізованих,	ко-
трим	 уводили	 0.3	 мг/кг	 кандесартану).	 Епізод	 фокальної	
ішемії	мозку	створювався	за	допомогою	90-хвилинної	оклю-
зії	лівої	середньої	церебральної	артерії;	оклюзія	супрово-
джувалася	24-годинною	реперфузією.	Неврологічний	дефі-
цит	оцінювався	в	балах	після	закінчення	періоду	реперфузії.	
Потім	тварини	рандомізовано	відбиралися	для	вимірювань	
трьох	видів:	об’єму	зони	інфаркту,	ступеня	набряку	мозку	з	
використанням	методу	„суха/волога	тканина”	та	концентра-
цій	малонового	діальдегіду	(MDA)	й	відновленого	глутаті-
ону	(GSH)	з	використанням	методики	HPLC.	Індукція	цере-
бральної	ішемії	у	відповідній	контрольній	групі	призводила	
до	розвитку	значних	інфарктів	у	корі	та	стріатумі,	спряже-
ному	з	важкими	порушеннями	моторних	функцій.	Уведення	
кандесартану	забезпечувало	істотне	зменшення	об’ємів	ін-
фарктів	і	послаблення	порушень	зазначених	функцій.	Вміст	
води	в	лівій	 (ураженій)	півкулі	в	контрольній	групі	з	 іше-
мією	був	значно	підвищеним.	Використання	кандесартану	
призводило	до	значного	зменшення	вмісту	води	в	ішемізова-
ній	лівій	півкулі,	відновлення	рівня	GSH	у	тканині	та	змен-
шення	продукції	MDA.	Отже,	блокування	AT1-рецепторів	
кандесартаном	може	помітно	зменшувати	 	ступінь	 ішеміч-
ного	пошкодження	мозку	та	послаблювати	формування	на-
бряку;	ці	ефекти	опосередковуються	підсиленням	антиокси-
дантної	активності.	
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